1-3 of 3
Horst Hummel
Close
Sort by
Journal Articles

A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma

Clinical Trials & Observations
Achim Rothe, Stephanie Sasse, Max S. Topp, Dennis A. Eichenauer, Horst Hummel, Katrin S. Reiners, Markus Dietlein, Georg Kuhnert, Joerg Kessler, Carolin Buerkle, Miroslav Ravic, Stefan Knackmuss, Jens-Peter Marschner, Elke Pogge von Strandmann, Peter Borchmann, Andreas Engert
Journal: Blood
Blood (2015) 125 (26): 4024–4031.
https://doi.org/10.1182/blood-2014-12-614636
Published: 2015
Journal Articles

A Phase I Study Of An Anti-CD30 x Anti-CD16A Bispecific Tandab Antibody, AFM13, In Patients With Relapsed Or Refractory Hodgkin Lymphoma

Eugene Zhukovsky, PhD, Achim Rothe, MD, Bastian von Tresckow, MD, Max Topp, Anas Younes, MD, Dennis A. Eichenauer, MD, Horst Hummel, MD, Katrin S. Reiners, PhD, Markus Dietlein, MD, Joerg Kessler, PhD, Miroslav Ravic, MD, PhD, Christian Hucke, PhD, Elke Poggevon Strandmann, PhD, Andreas Engert, MD
Journal: Blood
Blood (2013) 122 (21): 5116.
https://doi.org/10.1182/blood.V122.21.5116.5116
Published: 2013
Journal Articles

A Phase I Study with the Bispecific Anti-CD30 × Anti-CD16A Antibody Construct AFM13 in Patients with Relapsed or Refractory Hodgkin Lymphoma,

Achim Rothe, MD, Anas Younes, MD, Katrin S. Reiners, PhD, Markus Dietlein, MD, Dennis A. Eichenauer, MD, Joerg Kessler, Max S. Topp, MD, Horst Hummel, MD, Miroslav Ravic, MD, PhD, Christian Hucke, PhD, Elke Pogge von Strandmann, PhD, Andreas Engert, MD
Journal: Blood
Blood (2011) 118 (21): 3709.
https://doi.org/10.1182/blood.V118.21.3709.3709
Published: 2011